<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antiapoptotic B cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> 2 (BCL2) family proteins are expressed in many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, but the circumstances under which these proteins are necessary for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> maintenance are poorly understood </plain></SENT>
<SENT sid="1" pm="."><plain>We exploited a novel functional assay that uses BCL2 homology domain 3 (<z:chebi fb="0" ids="30153">BH3</z:chebi>) <z:chebi fb="7" ids="16670">peptides</z:chebi> to predict dependence on antiapoptotic proteins, a strategy we call <z:chebi fb="0" ids="30153">BH3</z:chebi> profiling </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="30153">BH3</z:chebi> profiling accurately predicts sensitivity to BCL2 <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 in primary <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) cells </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="30153">BH3</z:chebi> profiling also accurately distinguishes myeloid cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> sequence 1 (MCL1) from BCL2 dependence in <z:mp ids='MP_0009440'>myeloma</z:mp> cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>We show that the special sensitivity of CLL cells to BCL2 antagonism arises from the requirement that BCL2 tonically sequester proapoptotic BIM in CLL </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="5" ids="53329">ABT</z:chebi>-737 displaced BIM from BCL2's <z:chebi fb="0" ids="30153">BH3</z:chebi>-binding pocket, allowing BIM to activate BAX, induce <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> permeabilization, and rapidly commit the CLL cell to <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Our experiments demonstrate that BCL2 expression alone does not dictate sensitivity to <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 </plain></SENT>
<SENT sid="7" pm="."><plain>Instead, BCL2 complexed to BIM is the critical target for <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 in CLL </plain></SENT>
<SENT sid="8" pm="."><plain>An important implication is that in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, BCL2 may not effectively buffer chemotherapy <z:hpo ids='HP_0011420'>death</z:hpo> signals if it is already sequestering proapoptotic <z:chebi fb="0" ids="30153">BH3</z:chebi>-only proteins </plain></SENT>
<SENT sid="9" pm="."><plain>Indeed, activator <z:chebi fb="0" ids="30153">BH3</z:chebi>-only occupation of BCL2 may prime <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells for <z:hpo ids='HP_0011420'>death</z:hpo>, offering a potential explanation for the marked chemosensitivity of certain <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> that express abundant BCL2, such as CLL and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>